Latest Capital Management News

Immuron delivered record FY26 sales, a narrower loss and a much stronger cash balance, while shifting clinical development towards commercial partners. The annual report also flags a material weakness in inventory controls and confirms that IMM-529 remains dependent on a future licensing deal.

Paradigm will return the US$2 million drawn from Obsidian earlier this month and cancel the associated convertible notes, without an additional payment. The decision comes as the biotechnology company reviews interim data from its pivotal knee osteoarthritis trial and prepares a separate update on funding and operations.

Stealth Group has confirmed a $1.24940 Dividend Reinvestment Plan price for its fully franked 1.5-cent annual dividend. Shareholders choosing cash will be paid on 30 September, while reinvestment shares are scheduled for issue on 7 October.

WAM Capital’s investment portfolio fell 10.5% in FY2026, while Wilson Asset Management set an 8.0 cents per share target for the next financial year. The presentation points to a thin 0.7-year dividend reserve after the final payout, even as management argues small-cap valuations and takeover activity are improving.

BluGlass has agreed an A$8.0 million R&D-backed loan with Rockford, refinancing its existing Radium facility and adding about A$5.5 million of liquidity. The funding gives the laser developer more room to scale, but carries a 16.5% interest rate and repayment obligations tied to future tax refunds.

Centuria Industrial REIT delivered 4% growth in funds from operations for FY26 and expects another lift in FY27, supported by leasing momentum and embedded rental reversion. The opportunity comes with a more exposed interest-rate profile and a development pipeline that still depends on power, planning and execution.

Image Resources has secured a A$5 million cash advance from LB Group while negotiating a broader deal that could bring further funding and mineral sands processing equipment into its Durack and Yandanooka projects. The advance comes without issuing new shares, but the larger transaction remains unresolved.

Dimerix has drawn A$17 million from a non-dilutive facility, giving the biotech funding it says is sufficient to complete the ACTION3 Phase 3 trial of DMX-200 and continue developing DMX-652. A further A$17 million remains available, although repayment depends partly on future licensing income, milestones or capital-market access.

Nufarm expects FY26 underlying EBITDA to rise about 25% at the midpoint of its $370 million to $380 million range, while leverage falls from 2.7 times to approximately 2.0 times. The improvement comes alongside a sweeping cost-reduction program, but restructuring charges of up to $110 million post tax remain in the numbers.

GWR Group has completed a $19.85 million capital return, paying shareholders 6.1 cents per ordinary share. The distribution delivers the approved cash payout, but leaves the company’s post-return cash position undisclosed.

Yandal Resources posted its busiest exploration year yet, expanding the Arrakis discovery and ending FY2026 with 450,200 ounces of reported resources and $9.7 million in cash. But a larger loss, material going-concern uncertainty and a CEO transition leave the company needing to convert drilling momentum into resources and renewed funding support.

Harmoney will continue buying back up to 5% of its issued shares while reaffirming FY27 cash NPAT guidance of $16 million or more. The lender also says potential acquisitions could be funded without an equity raising, although no transaction has been announced.